60 Degrees Pharmaceuticals
SXTP
7 hedge funds and large institutions have $22.5K invested in 60 Degrees Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more ownership
Funds ownership: 0.26% → 0.26% (+0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
64% less capital invested
Capital invested by funds: $62.9K → $22.5K (-$40.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$25.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.17K |
| 3 |
Barclays
London,
United Kingdom
|
+$1.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$37.3K |
| 2 |
Citigroup
New York
|
-$278 |
SXTP Hedge Fund Activity: Q4 2025 in Review
7 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in 60 Degrees Pharmaceuticals (SXTP) for Q4 2025, worth a combined $22.5K — down 64% from $62.9K a quarter earlier.
Fund positioning in SXTP was balanced in Q4 2025: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $25.5K. The largest seller was DRW Securities, exiting entirely with an estimated $37.3K sold.
- 7 institutional investors held 60 Degrees Pharmaceuticals (SXTP) as of Q4 2025, unchanged from Q3 2025.
- Funds reported $22.5K of 60 Degrees Pharmaceuticals stock for Q4 2025, down 64% quarter-over-quarter.
- 2 funds opened new 60 Degrees Pharmaceuticals positions in Q4 2025 and 2 closed out, a net change of 0 holders.
- The largest 60 Degrees Pharmaceuticals buyer in Q4 2025 was Jane Street, an estimated $25.5K added.
- The largest 60 Degrees Pharmaceuticals seller in Q4 2025 was DRW Securities, an estimated $37.3K sold.
Based on aggregated 13F filings for Q4 2025.